Registry for people with parathyroid disease
Part of Hormones & metabolism clinical trials.
This trial is creating a registry (a database) for people with parathyroid disease. It will collect information to help doctors better understand and treat these conditions.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years old or older.
- You've been diagnosed with hyperparathyroidism (too much parathyroid hormone) or hypoparathyroidism (too little), based on blood tests.
- You are willing to give your written permission (informed consent) to join the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study is creating a database of people with hypoparathyroidism or pseudohypoparathyroidism in Italy. It may help researchers learn more about these conditions and improve future care.
This study is creating a registry for people with hypoparathyroidism (low calcium caused by not enough parathyroid hormone) or pseudo-hypoparathyroidism. It helps doctors learn more about these conditions and improve care.
This is a registry (data collection) study that gathers information about people diagnosed with chronic hypoparathyroidism in France. It helps researchers better understand how common it is and what it looks like in real life.
This study follows adults with hypoparathyroidism to better understand what symptoms and lab levels change over time. It may help doctors plan future treatments by learning the natural course of the condition, even if you already take standard medicines.
This trial tests an investigational drug called XH02 for people with hypoparathyroidism (low parathyroid hormone) that is not well controlled with standard calcium and vitamin D treatments. The goal is to see if XH02 is safe and effective at managing symptoms.
This trial is for adults with hypoparathyroidism who are already taking a drug called palopegteriparatide (TransCon PTH) at a certain dose. It tests whether higher doses of this drug can better control calcium levels and reduce the need for other supplements.
Hear when a new Hyperparathyroidism trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.